SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 6,632.17 |
| Enterprise Value ($M) | 6,330.11 |
| Book Value ($M) | 1,179.71 |
| Book Value / Share | 16.97 |
| Price / Book | 5.62 |
| NCAV ($M) | 425.79 |
| NCAV / Share | 6.12 |
| Price / NCAV | 15.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.18 |
| Return on Assets (ROA) | 0.26 |
| Return on Equity (ROE) | 0.52 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.56 |
| Current Ratio | 1.65 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,295.71 |
| Assets | 2,049.63 |
| Liabilities | 869.92 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Janus Henderson Group Plc | 5.20 | -9.44 | |
| 13G/A | Vanguard Group Inc | 10.18 | -3.78 | |
| 13G/A | BlackRock, Inc. | 12.60 | 4.71 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 171,106 | 517,303 | 33.08 | |
| 243,607 | 561,678 | 43.37 | |
| 174,988 | 650,204 | 26.91 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KROS – Keros Therapeutics, Inc. | KYMR – Kymera Therapeutics, Inc. |
| LGND – Ligand Pharmaceuticals Incorporated | LRMR – Larimar Therapeutics, Inc. |
| LXEO – Lexeo Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io